Executive Summary
Eight bullish federal IT & cybersecurity contracts totaling $643.8M obligated signal sustained U.S. government demand for systems sustainment, modernization, and SaaS through 2026-2032, with $367M already outlayed across mature awards. Deloitte Consulting LLP dominates with $174.6M (two HHS wins), while Accenture ($93.6M DHS) and small businesses like MINBURN ($86M GSA) highlight concentration in top-tier integrators and SDVOB/SDVOSB performers. Upside exceeds $500M from options/extensions, but firm fixed price structures and zero-outlay deals (~$295M) flag execution risks warranting close monitoring.
Tracking the trend? Catch up on the prior Federal IT & Cybersecurity Contracts digest from February 05, 2026.
Investment Signals(3)
- Dominance of IT consultancies in multi-year sustainment(HIGH)β²
Deloitte ($174.6M HHS) and Accenture ($93.6M DHS) lead with 50%+ of total value in long-term (5-10yr) IT maintenance/modernization, $215M outlayed signaling strong cash flow visibility.
- Small/SDVOB businesses winning large full/open awards(HIGH)β²
MINBURN ($86M GSA Army SaaS), REI ($80.7M GSA QA), and IT Federal ($67.6M Treasury) capture 35% of value despite no set-asides, with $64.7M outlayed in IT Federal.
- High execution rates in 5+ yr contracts(MEDIUM)β²
58% average outlay rate ($367M of $644M) in deals like Accenture (71%), Deloitte FDA (97%), and IT Federal (96%), supporting revenue predictability to 2027+.
Risk Flags(2)
- Execution[HIGH RISK]βΌ
Firm fixed price in 6/8 contracts (~$500M) exposes to cost overruns amid long periods (avg 4-5yrs remaining); subawards average 20% of value ($100M+ across 200+ subs) add dependency.
- Market[MEDIUM RISK]βΌ
Zero outlays in 4 contracts ($295M, 46% of total) like MINBURN, REI, Leidos signal funding delays; budget reprioritization risks in extended terms to 2032.
Opportunities(3)
- β
$500M+ unexercised options (e.g., Deloitte NIH $245M upside, MINBURN $145M) plus extensions to 2029-2032 across 7/8 deals.
- β
Follow-on potential in HHS IT modernization (25% of value: $174M Deloitte + $73M GDIT CMS) and GSA vehicles for SaaS/sustainment.
- β
Small/SDVOB leverage for repeat wins despite full/open comp, with high outlay execution positioning for local DoD/Treasury expansions.
Sector Themes(3)
- β
HHS awards total $248M (38% of period value) focused on NIH/FDA/CMS systems integration/modernization through 2026-2031.
- β
Four GSA deals ($295M, 46%) via BPA calls for SaaS/QA/sustainment, favoring incumbents and small businesses.
- β
75% of value in 5+ year terms with options/extensions to 2032, averaging $80M/contract.
Watch List(3)
- π
{"entity"=>"Deloitte Consulting LLP", "reason"=>"Largest exposure at $174.6M (27%) across two HHS IT deals with $100M+ options upside.", "trigger"=>"NIH/FDA option exercises or follow-on awards >$100M"}
- π
{"entity"=>"MINBURN Technology Group LLC", "reason"=>"$86M zero-outlay GSA SaaS deal with $145M potential; SDVOB status in full/open win.", "trigger"=>"Initial outlays >20% or Army DOD365 expansion"}
- π
{"entity"=>"Zero-outlay contracts ($295M total)", "reason"=>"46% of value at risk of delay (MINBURN, REI, Leidos, partial others).", "trigger"=>"Outlay ramp >$50M by mid-2026"}
Get daily alerts with 3 investment signals, 2 risk alerts, 3 opportunities and full AI analysis of all 8 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC